Skip to content
Biotechnology

120 German Hospitals legally entitled to negotiate fee for OncoSil

OncoSil Medical Limited (ASX:OSL) 2 mins read

Sydney, Australia – 04 February 2025: Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce that German Institute for the Hospital Remuneration System (InEK) has authorised 120 German hospitals to negotiate funding for the OncoSil™ device classification under the innovation funding (NUB) program with the statutory health insurance (SHI) companies during the annual budget negotiations. This represents a significant increase of 43% compared to 2024 (84 hospitals), underscoring the demand in Germany and growing recognition of the OncoSil™ device within the German healthcare system.

OncoSil had been granted a “Positive Status 1” classification under the innovation funding (NUB) program in 2021. In October 2024; the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) approved the Directive for testing the new treatment method: "Endoscopic injection-implantation of 32Plabeled microparticles in unresectable, locally advanced pancreatic tumors.” Following that in January 2025, the Ministry of Health approval has been received and the Coverage with Evidence Development Study Directive has been published in the National German Gazette.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

“We are delighted by the continued progress in Germany with the expanded authorisation for hospitals to negotiate funding for the OncoSil™ device under the NUB innovation program. This important milestone reflects growing acceptance of the OncoSil device by the German healthcare professionals on the clinical potential of our treatment and reinforces our commitment to delivering life-changing solutions for patients with locally advanced pancreatic cancer. The approval from the German Ministry of Health and the publication of the Coverage with Evidence Development Study Directive further solidifies our position in this important market. We remain dedicated to advancing innovative treatments that improve patient outcomes worldwide."

Read the announcement here


 


About us:

About OncoSil Medical
OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for longterm survival.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy. 

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com


Contact details:

For more information, please contact:

Mr. Nigel Lange
CEO & Managing Director
E: nigel.lange@oncosil.com
T: +49 30 300 149 3043

Mr. Christian Dal Cin
CFO & Company Secretary
E: c.dalcin@acclime.com
T: +61 3 9824 5254

Media & Investor Enquiries
Ms. Julia Maguire
The Capital Network
Media and Investor Enquiries
E: julia@thecapitalnetwork.com.au
T: +61 2 8999 3699

More from this category

  • Biotechnology
  • 13/02/2025
  • 03:14
Monash University

Stronger, safer, smarter: pioneering Zinc-based dissolvable implants for better bone repair

Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates…

  • Contains:
  • Biotechnology
  • 12/02/2025
  • 11:19
BTC Health Limited (ASX:BTC)

BTC announces CFO and Company Secretary appointment

Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce the appointment ofSalesh Balak as Chief Financial Officer and Company Secretary, effective 17 March 2025.This appointment reflects the underlying expansion of theBTC business, and the appointment of Josh Kahanovitz, current Head of Finance, into the role of Chief Operating Officer from 17 March 2025. Salesh joins BTC from Universal Biosensors Australia, where he was the Chief Financial Officer and Company Secretary for more than 18 years. He is a member of the Institute of Chartered Accountants, (CA) and Certified Practicing Accountants (CPA). BTC’s current Company Secretary,…

  • Biotechnology
  • 10/02/2025
  • 11:48
BTC Health Limited (ASX:BTC)

BTC expands distribution partnership with Arna Pharma

• License and distribution agreement forBronchitol and Aridol converted from an initial 10- year term to an indefinite license • BTC to earn royalties from sales ofBronchitol and Aridol in Singapore and Malaysia • BTC granted first right of refusal to Arna Pharma's new product pipeline Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce that its whollyowned investee company, BTC Pharma, has amended its existing License and Distribution Agreement for the Bronchitol and Aridol products (Products) and extended its partnership with Arna Pharma, with effect from 1 February 2025. Under the terms of the…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.